Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
ANTI-TUMOR IMMUNOTHERAPY ENHANCER
Document Type and Number:
WIPO Patent Application WO/2019/004464
Kind Code:
A1
Abstract:
The purpose of the present invention is to provide a composition for inhibiting the proliferation and/or infiltration of tumor cells, an enhancer of an anti-tumor effect of a drug for the purpose of removing immunosuppression associated with cancer, or the like, which is characterized by being used for a specific subject. The present invention relates to a composition for inhibiting the proliferation and/or the infiltration of tumor cells, or an enhancer of an anti-tumor effect of a drug for the purpose of removing immunosuppression associated with cancer, wherein the composition or the enhancer contains a phosphorylation inhibitor or a dephosphorylation agent for the phosphorylation of a tyrosine residue located at position-111 and/or position-249 in human IDO1 or a position in non-human IDO1 which corresponds to position-111 and/or position-249 in human IDO1, and the composition or the enhancer can be used against tumor cells in which the tyrosine residue is phosphorylated and/or can be used in a subject who carries the tumor cells.

Inventors:
TSUKAMOTO NOBUO (JP)
KAWAKAMI YUTAKA (JP)
Application Number:
PCT/JP2018/024950
Publication Date:
January 03, 2019
Filing Date:
June 29, 2018
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
UNIV KEIO (JP)
International Classes:
A61K31/4365; A61K45/00; A61K31/4709; A61K31/496; A61K31/5025; A61K31/506; A61K31/517; A61K39/395; A61P35/00; A61P43/00; C07K16/40; C12Q1/26; G01N33/15; G01N33/50; G01N33/68; C07D215/54; C07D401/14; C07D405/14; C07D417/12; C07D487/04; C07D495/04; C12N15/53
Other References:
BELGUISE K. ET AL.: "Green tea polyphenols reverse cooperation between c-Rel and CK2 that induces the aryl hydrocarbon receptor, Slug, and invasive phenotype", CANCER RES., vol. 67, no. 24, 15 December 2007 (2007-12-15), pages 11742 - 11750, XP055677382, DOI: 10.1158/0008-5472.CAN-07-2730
TSUKAMOTO N. ET AL.: "3-A-W22-25-P Signal crosstalk of aryl hydrocarbon receptor (AhR) and IDO phosphorylation in tumor microenvironment", PROCEEDINGS OF THE 45TH ANNUAL MEETING OF THE JAPANESE SOCIETY FOR IMMUNOLOGY; DECEMBER 5-7, 2016, vol. 45, 14 November 2016 (2016-11-14), pages 133, XP009519867
MONDANELLI G. ET AL.: "A relay pathway between arginine and tryptophan metabolism confers immunosuppressive properties on dendritic cells", IMMUNITY, vol. 46, 14 February 2017 (2017-02-14), pages 233 - 244, XP029929845, DOI: 10.1016/j.immuni.2017.01.005
ALBINI E. ET AL.: "Distinct roles of immunoreceptor tyrosine-based motifs in immunosuppressive indoleamine 2,3-dioxygenase 1", J CELL MOL MED., vol. 21, no. 1, 30 September 2016 (2016-09-30), pages 165 - 176, XP055677384, DOI: 10.1111/jcmm.12954
COLETTI A. ET AL.: "Advances in indoleamine 2,3-dioxygenase 1 medicinal chemistry", MED CHEM COMMUN., vol. 8, 16 May 2017 (2017-05-16), pages 1378 - 1392, XP055677388, DOI: 10.1039/C7MD00109F
BUETTNER R. ET AL.: "Inhibition of src family kinases with dasatinib blocks migration and invasion of human melanoma cells", MOL CANCER RES., vol. 6, no. 11, November 2008 (2008-11-01), pages 1766 - 1774, XP055677392
MERLO LMF. ET AL.: "Therapeutic antibody targeting of indoleamine-2,3-dioxygenase(IDO2) inhibits autoimmune arthritis", CLIN IMMUNOL., vol. 17 9, 20 February 2017 (2017-02-20), pages 8 - 16, XP085069283, DOI: 10.1016/j.clim.2017.01.016
WANG Y. ET AL.: "FAK/PYK2 inhibition enhances immune checkpoint inhibitor efficacy", CANCER RES., vol. 76, no. 14 suppl., 568, July 2016 (2016-07-01), XP055683150, DOI: 10.1158/1538-7445.AM2016-568
CHEONG JE. ET AL.: "Targeting the IDO1/TD02-KYN-AhR pathway for cancer immunotherapy - challenges and opportunities", TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 3 9, no. 3, 15 December 2017 (2017-12-15), pages 307 - 325, XP055677414, DOI: 10.1016/j.tips.2017.11.007
Attorney, Agent or Firm:
TANAKA Shinichiro et al. (JP)
Download PDF: